ABOUT / EDITORIAL METHOD
A calm desk for a complicated literature
How this independent digest separates what is known, what is proposed, and what remains unanswered.
What this site covers
Antineoplaston Peptides is an independent literature digest about three named compounds: Thymosin Alpha-1, thymulin, and KPV. The editorial frame is immune and thymic signaling, led by research on Thymosin Alpha-1 as a possible adjunct in oncology settings. Thymulin adds zinc-dependent thymic and neuroendocrine context. KPV adds preclinical anti-inflammatory and transporter biology.
The title does not define the evidence reviewed. This site does not evaluate antineoplaston preparations, their proposed ingredients, or cancer-treatment claims associated with them. It does not sell peptides, operate a clinic, or provide treatment guidance. Its task is to make a composed source set easier to read without smoothing away differences among compounds or study designs.
How the evidence is organized
Each compound page follows the same sequence: a plain-language opening, molecular identity, mechanism, cited findings, reported effects and cautions, then placement within the wider theme. Consistent structure makes comparison possible, but it does not imply equal evidence. Thymosin Alpha-1 includes randomized human studies and review literature [1][2][4][5]. Thymulin is supported chiefly by reviews and animal or gene-therapy experiments [8][9][10][11][12]. KPV is supported by cell work, mouse inflammatory models, and delivery-formulation studies [13][14][15][16][17].
Study labels are retained because they define what a result can answer. Cell experiments clarify pathways. Animal models explore biological plausibility. Retrospective human studies identify associations. Randomized trials test specific clinical questions with stronger control of bias. Reviews organize a field but depend on the quality of the underlying studies. A positive result at one level does not automatically predict another.
Editorial stance
The site uses neutral language and gives negative or limiting results the same visibility as favorable signals. The large TESTS sepsis trial is therefore central to the Thymosin Alpha-1 account: it found no statistically significant mortality difference even though earlier work had appeared more encouraging [1][5]. For thymulin and KPV, the absence of a mature human clinical record is stated directly.
Community reports appear only where the composed corpus provides them. They are labeled as anecdotal and separated from clinical findings. Missing reports are not filled with web lore. Safety language distinguishes documented adverse events, theoretical mechanism-based cautions, evidence gaps, and quality risks from unregulated material. The site does not provide doses or recommend use.
How to use the references
Bracketed numbers connect claims to the reference index. The list preserves the supplied citation record and groups no studies into a hidden score. A reader can check the study title, journal, year, and source link, then return to the page to see how the finding was framed.
The comparison page is the best entry point for evidence maturity. The compound pages provide depth, while the FAQ answers narrower questions. Across all pages, the same rule applies: findings stay attached to the molecule, model, delivery system, and outcome actually studied. That keeps an engineered nanoparticle experiment from becoming a claim about free peptide, and an adjunct review from becoming a claim of independent cancer treatment.